Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics (Q36120821)

12 August 2017

1 reference

title

Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics (English)

1 reference

12 August 2017

1 reference

Hsien-Yuan Lane

1

1 reference

12 August 2017

Cheng-Chun Lee

series ordinal

2

1 reference

12 August 2017

Yi-Ching Liu

series ordinal

3

1 reference

12 August 2017

Wen-Ho Chang

series ordinal

4

1 reference

12 August 2017

publication date

1 March 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

139-149

1 reference

Positive and negative symptoms in schizophrenia. A critical reappraisal

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Assessment of Enduring Deficit and Negative Symptom Subtypes in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

The role of serotonin in antipsychotic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Sustained attention deficits as markers of genetic susceptibility to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Clinical applications of pharmacogenetics in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Pharmacogenomics in schizophrenia: the quest for individualized therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Pharmacogenetics of psychotropic drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Computational roles for dopamine in behavioural control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Anxiogenic-like effects and reduced stereological counting of immunolabelled 5-hydroxytryptamine6 receptors in rat nucleus accumbens by antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Effects of the 5-HT(6) receptor antagonist Ro 04-6790 on learning consolidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Cytochrome P450 polymorphisms and response to antipsychotic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Genome-based pharmacogenetics and the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Pharmacogenomics: bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Pharmacogenetics and drug development: the path to safer and more effective drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

SNPs and pharmacogenomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Effects of Gender and Age on Plasma Levels of Clozapine and Its Metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Functional analysis of the human D2 dopamine receptor missense variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Use of unlinked genetic markers to detect population stratification in association studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Genomic control for association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Revisiting the factor structure for positive and negative symptoms: evidence from a large heterogeneous group of psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Pharmacogenetic prediction of clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

Pharmacogenetics of clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.6.2.139

21 January 2018

Identifiers

DOI

10.1517/14622416.6.2.139

1 reference

12 August 2017

1 reference